Axol Bioscience announced it has raised $2.8 million (£2.1 million) in funding to expand its US operations, advance product development, and scale cell manufacturing capacity. The financing was led by US life sciences investor BroadOak Capital Partners, with participation from Axol’s founding investor, the Roslin Foundation. Axol said the capital will support growth of its commercial presence in the US while also enabling development of enhanced induced pluripotent stem cell (iPSC)-derived models in neuroscience, ophthalmology, and cardiovascular disease.
The company, which develops and supplies iPSC-derived cells, reagents, and specialist services for drug discovery and disease research, said it plans to expand manufacturing at its base in the Roslin Innovation Centre in Edinburgh to meet increasing global demand for human-relevant in vitro disease models. Axol has positioned itself as a provider of physiologically relevant models for neurodegenerative disorders, including Huntington’s disease and sporadic amyotrophic lateral sclerosis (ALS/MND).
The company tied the raise to recent operating momentum, citing 45% revenue growth in 2025 and 36% growth in 2024. Chief Financial Officer Oliver Richardson said the funding will help Axol strengthen its US footprint and expand manufacturing capacity at its Edinburgh site to keep pace with demand.
KEY QUOTES:
“We’re proud to partner with BroadOak, a global leader in life sciences investing. Their expertise and support, alongside our long-term partner Roslin Foundation, reflects confidence in our long-term vision, team, products, and technology as we scale operations and expand internationally,”
Liam Taylor, CEO, Axol Bioscience
“Following Axol’s 45% revenue growth in 2025 and 36% in 2024, this funding allows us to strengthen our US operations and expand manufacturing capacity at our Edinburgh site, ensuring we can continue to meet increasing global demand,”
Oliver Richardson, CFO, Axol Bioscience
“Axol is a leader in their space and is well positioned as global regulators actively usher in the adoption of cell-based models. We are excited to be partnering with Liam, Oli, and the entire Axol team to support their next phase of growth,”
Daniel Friedman, Managing Director, BroadOak Capital Partners
